Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients

Acta Pharmacologica Sinica

Volumn 27, Issue 11, 2006, Pages 1504-1508

  Chu, Xiao Man ^a   Hao, Hai Ping ^b   Wang, Guang Ji ^b   Guo, Lian Qing ^a   Min, Pei Qing ^a  

^a NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cyclosporine; CYP3A5; Genetic polymorphism; Metabolic ratio; Renal transplant patients

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A5; DEXAMETHASONE; DRUG METABOLITE;

ALLELE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 33750344807     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00428.x     Document Type: Article

References (16)

1. Guengerich FP. Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 1991; 266: 10019-22.
2. Evans WE, Mcleod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
3. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30: 1491-6.
4. Hustert E, Haber M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11: 773-9.
5. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization if the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
6. Min DI, Ku YM, Vichiendilokkul A, Fleckenstein LL. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy 1999; 19: 753-9.
7. Hesselink DA, van-Schaik RH, van-der-Heiden IP, van-der-Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
8. Anglicheau D, Thervet E, Etienne I, Hurault DLB, Le MY, Touchard G, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin pharmacol Ther 2004; 75: 422-33.
9. Hesselink DA, van-Gelder T, van-Schaik RH, Balk AH, van-der-Heiden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphism in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-56.
10. Haufroid V, Mourad M, Van KV, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphism on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-54.
11. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59-66.
12. Wallemacq PE, Alexandre K. Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and emit cyclosporine assays. Clin Chem 1999; 45: 432-35.
13. Williams JA, Cook J, Susan I, Hurst SI. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003; 31: 1526-30.
14. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555-64.
15. Aros CA, Ardiles LG, Schneider HO, Flores CA, Alruiz PA, Jerez VR, et al. No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. Transplant Proc 2005; 37: 3364-6.
16. Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995; 28: 547-59.